Key result
CD14++CD16+ monocyte subsets drive myocardial inflammation and fibrosis in heart failure and AF.
Why the study?
Distinct monocyte subsets have potential for beneficial or detrimental effects on HF and AF pathogenesis, but few studies have specifically examined their characteristics as contributors to cardiac fibrosis and AF, and translation from animal studies to human research has been limited.
This narrative review synthesizes evidence on how distinct monocyte subsets (particularly Mon2) mediate inflammation and cardiac fibrosis linking heart failure and atrial fibrillation, highlighting potential targets for future immunomodulatory therapies.
Answers are grounded in this paper and cite their sources.
Mon2 may be a viable immunomodulatory target in HF and AF; leaves open whether subset-specific interventions improve outcomes.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Shahid et al. (2018) conducted a review in Heart Failure and Atrial Fibrillation. Monocyte subsets (Mon1, Mon2, Mon3) and associated inflammatory cells was evaluated on Pathogenesis of cardiac fibrosis, heart failure, and atrial fibrillation. Monocyte subsets, notably CD14++CD16+, drive myocardial inflammation and fibrosis in heart failure and atrial fibrillation, offering potential therapeutic targets.
Synapse has enriched 10 related papers. Consider them for comparative context: